TY - JOUR
T1 - Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients
AU - Anaissie, Elias J.
AU - Fainstein, Victor
AU - Bodey, Gerald P.
AU - Rolston, Kenneth
AU - Elting, Linda
AU - Kantarjian, Hagop
AU - Cabanillas, Fernando
AU - McCredie, Kenneth B.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1988/3
Y1 - 1988/3
N2 - A three-arm prospective randomized trial was designed to compare the efficacies of piperacillin plus vancomycin, ceftazidime plus vancomycin, or all three drugs as initial therapy for fever in neutropenic cancer patients. The objectives were to determine whether a broad-spectrum penicillin was as effective as a broad-spectrum cephalosporin and whether two beta-lactam antibiotics were more effective than one. Four hundred and seventy of the 519 febrile episodes entered in the study could be evaluated for response. Ceftazidime plus vancomycin was significantly more effective than piperacillin plus vancomycin, considering all febrile episodes (79 percent versus 61 percent, p = 0.001), documented infections (79 percent versus 57 percent, p = 0.004), gram-negative infections (88 percent versus 47 percent, p = 0.001), and bacteremias (81 percent versus 51 percent, p = 0.01). The addition of piperacillin to ceftazidime (piperacillin plus ceftazidime and vancomycin versus ceftazidime plus vancomycin) did not improve the response rate and was associated with a significantly higher incidence of skin rash. Vancomycin plus ceftazidime provides adequate antibiotic coverage for initial treatment of fever in neutropenic patients. This combination was equally effective, less expensive, and less toxic than the double beta-lactam combination used in this study.
AB - A three-arm prospective randomized trial was designed to compare the efficacies of piperacillin plus vancomycin, ceftazidime plus vancomycin, or all three drugs as initial therapy for fever in neutropenic cancer patients. The objectives were to determine whether a broad-spectrum penicillin was as effective as a broad-spectrum cephalosporin and whether two beta-lactam antibiotics were more effective than one. Four hundred and seventy of the 519 febrile episodes entered in the study could be evaluated for response. Ceftazidime plus vancomycin was significantly more effective than piperacillin plus vancomycin, considering all febrile episodes (79 percent versus 61 percent, p = 0.001), documented infections (79 percent versus 57 percent, p = 0.004), gram-negative infections (88 percent versus 47 percent, p = 0.001), and bacteremias (81 percent versus 51 percent, p = 0.01). The addition of piperacillin to ceftazidime (piperacillin plus ceftazidime and vancomycin versus ceftazidime plus vancomycin) did not improve the response rate and was associated with a significantly higher incidence of skin rash. Vancomycin plus ceftazidime provides adequate antibiotic coverage for initial treatment of fever in neutropenic patients. This combination was equally effective, less expensive, and less toxic than the double beta-lactam combination used in this study.
UR - http://www.scopus.com/inward/record.url?scp=0023968101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023968101&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(88)90140-4
DO - 10.1016/0002-9343(88)90140-4
M3 - Article
C2 - 3279774
AN - SCOPUS:0023968101
SN - 0002-9343
VL - 84
SP - 581
EP - 589
JO - The American journal of medicine
JF - The American journal of medicine
IS - 3 PART 2
ER -